Abstract
INTRODUCTION OR HYPOTHESIS: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib's efficacy in treating thymic neuroendocrine tumors (TNETs). This study aimed to evaluate the efficacy and safety of surufatinib in well-differentiated TNETs by conducting a single center retrospective analysis. METHODS: We conducted a retrospective study at Fudan University Shanghai Cancer Center, including 102 patients with TNETs. This study assessed the efficacy and safety of surufatinib in this population. RESULTS: Median progression-free survival was 10.0 months, ORR was 5.6%, and DCR was 83.1%. Surufatinib performed better in first-line treatment compared to secondary treatment in terms of ORR, DCR, and mPFS. The most common adverse events were diarrhea (15.7%), hypertension (19.1%), proteinuria (13.5%), and hypothyroidism (5.6%). About 33.3% of patients required dosage reduction from 300 mg/day to 200 mg/day (or 250 mg/day) due to adverse events, which in most cases were mitigated or disappeared with dose reduction. CONCLUSIONS: For patients with advanced, progressive, well-differentiated TNETs, Surufatinib can be used as an option with a high mPFS and DCR. Moreover, the safety profile of surufatinib was found to be acceptable. These findings suggest that surufatinib could potentially serve as an innovative therapeutic option for this particular patient population.